Comprehensive Stock Comparison
Compare XOMA Royalty Corp. (XOMA) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  XOMA | 498.7% revenue growth vs REGN's 1.0% |
| Value |  REGN | Lower P/E (17.4x vs 39.7x) |
| Quality / Margins | XOMA | 41.1% net margin vs REGN's 31.4% |
| Stability / Safety | REGN | Beta 0.58 vs XOMA's 0.82, lower leverage |
| Dividends | XOMA | 1.8% yield, vs REGN's 0.4% |
| Momentum (1Y) | XOMA | +22.5% vs REGN's +15.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs XOMA's 7.3%, ROIC 12.4% vs -37.6% |
Who Each Stock Is For
Income & stability
REGNDividend streak 1 yrs, beta 0.58, yield 0.4%
Growth exposure
XOMARev growth 498.7%, EPS growth 59.2%, 3Y rev CAGR -9.3%
Long-term compounding (10Y)
REGN94.0% 10Y total return vs XOMA's 46.9%
Sleep-well-at-night portfolio
REGNLower volatility, beta 0.58, Low D/E 8.7%, current ratio 4.77x
Defensive / Recession hedge
XOMABeta 0.82, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
XOMA Royalty Corp is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets—typically earning a percentage of future drug sales if the therapies succeed. The company's moat lies in its specialized expertise in evaluating clinical-stage assets and structuring royalty agreements that provide diversified exposure to potential blockbuster drugs without bearing development costs.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
REGN 3XOMA 1XOMA4/6 metricsREGN3/4 metricsREGN7/9 metricsREGN2/2 metricsREGN leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). XOMA leads in 1 (Financial Metrics). 2 tied.
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 304.5x XOMA's $47M. XOMA is the more profitable business, keeping 41.1% of every revenue dollar as net income compared to REGN's 31.4%. On growth, XOMA holds the edge at +29.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XOMAXOMA Royalty Corp. | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $47M | $14.3B |
| EBITDAEarnings before interest/tax | $22M | $4.2B |
| Net IncomeAfter-tax profit | $19M | $4.5B |
| Free Cash FlowCash after capex | $5M | $3.2B |
| Gross MarginGross profit ÷ Revenue | +93.8% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +25.7% |
| Net MarginNet income ÷ Revenue | +41.1% | +31.4% |
| FCF MarginFCF ÷ Revenue | +11.4% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.9% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +144.0% | -2.5% |
Valuation Metrics
| Metric | XOMAXOMA Royalty Corp. | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $316M | $108.4B |
| Enterprise ValueMkt cap + debt − cash | $334M | $92.2B |
| Trailing P/EPrice ÷ TTM EPS | -16.03x | 18.99x |
| Forward P/EPrice ÷ next-FY EPS est. | 39.71x | 17.38x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.00x |
| EV / EBITDAEnterprise value multiple | — | 21.83x |
| Price / SalesMarket cap ÷ Revenue | 11.10x | 7.55x |
| Price / BookPrice ÷ Book value/share | 3.78x | 2.74x |
| Price / FCFMarket cap ÷ FCF | — | 26.56x |
Profitability & Efficiency
XOMA delivers a 17.9% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $14 for REGN. REGN carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.46x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs XOMA's 4/9, reflecting strong financial health.
| Metric | XOMAXOMA Royalty Corp. | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | +17.9% | +14.4% |
| ROA (TTM)Return on assets | +7.3% | +11.1% |
| ROICReturn on invested capital | -37.6% | +12.4% |
| ROCEReturn on capital employed | -19.4% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 1.46x | 0.09x |
| Net DebtTotal debt minus cash | $18M | -$16.2B |
| Cash & Equiv.Liquid assets | $102M | $18.9B |
| Total DebtShort + long-term debt | $119M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 0.67x | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $17,161 today (with dividends reinvested), compared to $7,158 for XOMA. Over the past 12 months, XOMA leads with a +22.5% total return vs REGN's +15.1%. The 3-year compound annual growth rate (CAGR) favors XOMA at 7.4% vs REGN's 0.5% — a key indicator of consistent wealth creation.
| Metric | XOMAXOMA Royalty Corp. | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | -5.5% | +1.6% |
| 1-Year ReturnPast 12 months | +22.5% | +15.1% |
| 3-Year ReturnCumulative with dividends | +23.9% | +1.5% |
| 5-Year ReturnCumulative with dividends | -28.4% | +71.6% |
| 10-Year ReturnCumulative with dividends | +46.9% | +94.0% |
| CAGR (3Y)Annualised 3-year return | +7.4% | +0.5% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than XOMA's 0.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.9% from its 52-week high vs XOMA's 66.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XOMAXOMA Royalty Corp. | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 0.58x |
| 52-Week HighHighest price in past year | $39.92 | $821.11 |
| 52-Week LowLowest price in past year | $18.35 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +66.3% | +95.9% |
| RSI (14)Momentum oscillator 0–100 | 49.0 | 47.5 |
| Avg Volume (50D)Average daily shares traded | 482K | 762K |
Analyst Outlook
Wall Street rates XOMA as "Buy" and REGN as "Buy". Consensus price targets imply 158.0% upside for XOMA (target: $68) vs 8.8% for REGN (target: $857). For income investors, XOMA offers the higher dividend yield at 1.77% vs REGN's 0.43%.
| Metric | XOMAXOMA Royalty Corp. | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $68.25 | $857.17 |
| # AnalystsCovering analysts | 10 | 48 |
| Dividend YieldAnnual dividend ÷ price | +1.8% | +0.4% |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | $0.47 | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 100 | 113.81 | +13.8% |
| Regeneron Pharmaceu… (REGN) | 100 | 161.99 | +62.0% |
Regeneron Pharmaceu… (REGN) returned +72% over 5 years vs XOMA Royalty Corp. (XOMA)'s -28%. A $10,000 investment in REGN 5 years ago would be worth $17,161 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | $6M | $28M | +412.0% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | -9.6% | -48.5% | -404.3% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 48.8 | 32.1 | -34.2% |
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
XOMA Royalty Corp. has traded in a 32x–57x P/E range over 3 years; current trailing P/E is ~-16x. Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | -8.89 | -1.65 | +81.4% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
XOMA Royalty Corp. generated $-14M FCF in 2024 (-260% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
XOMA vs REGN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is XOMA or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 19.0x trailing P/E (17.4x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XOMA or REGN?
On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 17.4x.
03Which is the better long-term investment — XOMA or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +71.6%, compared to -28.4% for XOMA Royalty Corp. (XOMA). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +94.0% versus XOMA's +46.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XOMA or REGN?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus XOMA Royalty Corp.'s 0.82β — meaning XOMA is approximately 42% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 146% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
05Which has better profit margins — XOMA or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus -48.5% for XOMA Royalty Corp. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus -140.3% for XOMA. At the gross margin level — before operating expenses — XOMA leads at 99.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is XOMA or REGN more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 17.4x forward P/E versus 39.7x for XOMA Royalty Corp. — 22.3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XOMA: 158.0% to $68.25.
07Which pays a better dividend — XOMA or REGN?
All stocks in this comparison pay dividends. XOMA Royalty Corp. (XOMA) offers the highest yield at 1.8%, versus 0.4% for Regeneron Pharmaceuticals, Inc. (REGN).
08Is XOMA or REGN better for a retirement portfolio?
For long-horizon retirement investors, XOMA Royalty Corp. (XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.82), 1.8% yield). Both have compounded well over 10 years (XOMA: +46.9%, REGN: +94.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between XOMA and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. XOMA pays a dividend while REGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.